

# Daniel Y C Heng

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2477127/publications.pdf>

Version: 2024-02-01

135  
papers

11,721  
citations

53660

45  
h-index

29081

104  
g-index

137  
all docs

137  
docs citations

137  
times ranked

9824  
citing authors

| #  | ARTICLE  | IF  | CITATIONS |
|----|--|-----|-----------|
| 1  | Outcomes of Cytoreductive Nephrectomy for Patients with Metastatic Renal Cell Carcinoma: Real World Data from Canadian Centers. <i>European Urology Focus</i> , 2022, 8, 1703-1710.  | 1.6 | 5         |
| 2  | Treatment Selection in First-line Metastatic Renal Cell Carcinoma—The Contemporary Treatment Paradigm in the Age of Combination Therapy. <i>JAMA Oncology</i> , 2022, 8, 292.  | 3.4 | 35        |
| 3  | Integrative clinical and molecular characterization of translocation renal cell carcinoma. <i>Cell Reports</i> , 2022, 38, 110190.   | 2.9 | 40        |
| 4  | Efficacy and Safety of First-line Systemic Therapy for Metastatic Renal Cell Carcinoma: A Systematic Review and Network Meta-analysis. <i>European Urology Open Science</i> , 2022, 37, 14-26.                             | 0.2 | 48        |
| 5  | Impact of Body Mass Index on Survival Outcomes of Patients with Metastatic Renal Cell Carcinoma in the Immuno-oncology Era: A Systematic Review and Meta-analysis. <i>European Urology Open Science</i> , 2022, 39, 62-71. | 0.2 | 9         |
| 6  | Utilization and Safety of Ipilimumab Plus Nivolumab in a Real-World Cohort of Metastatic Renal Cell Carcinoma Patients. <i>Clinical Genitourinary Cancer</i> , 2022, 20, 210-218.  | 0.9 | 4         |
| 7  | Imaging Response to Contemporary Immuno-oncology Combination Therapies in Patients With Metastatic Renal Cell Carcinoma. <i>JAMA Network Open</i> , 2022, 5, e2216379.   | 2.8 | 10        |
| 8  | Outcomes of patients with advanced non-clear cell renal cell carcinoma treated with first-line immune checkpoint inhibitor therapy. <i>European Journal of Cancer</i> , 2022, 171, 124-132.                                | 1.3 | 14        |
| 9  | Evolving landscape of first-line combination therapy in advanced renal cancer: a systematic review. <i>Therapeutic Advances in Medical Oncology</i> , 2022, 14, 175883592211086.   | 1.4 | 15        |
| 10 | Stage migration of testicular germ cell tumours in Alberta, Canada, during the COVID-19 pandemic: a retrospective cohort study. <i>CMAJ Open</i> , 2022, 10, E633-E642.  | 1.1 | 1         |
| 11 | Outcomes of Patients with Metastatic Renal Cell Carcinoma Treated with Targeted Therapy After Immuno-oncology Checkpoint Inhibitors. <i>European Urology Oncology</i> , 2021, 4, 102-111.                                  | 2.6 | 26        |
| 12 | New approaches to first-line treatment of advanced renal cell carcinoma. <i>Therapeutic Advances in Medical Oncology</i> , 2021, 13, 175883592110347.  | 1.4 | 25        |
| 13 | Impact of Time to Surgery and Surgical Delay on Oncologic Outcomes for Renal Cell Carcinoma. <i>Journal of Urology</i> , 2021, 205, 78-85.   | 0.2 | 11        |
| 14 | Reply By Authors. <i>Journal of Urology</i> , 2021, 205, 84-85.  | 0.2 | 0         |
| 15 | Evaluation of Clear Cell, Papillary, and Chromophobe Renal Cell Carcinoma Metastasis Sites and Association With Survival. <i>JAMA Network Open</i> , 2021, 4, e2021869.  | 2.8 | 104       |
| 16 | A comparison of sunitinib with cabozantinib, crizotinib, and savolitinib for treatment of advanced papillary renal cell carcinoma: a randomised, open-label, phase 2 trial. <i>Lancet, The</i> , 2021, 397, 695-703.       | 6.3 | 146       |
| 17 | Risk Prediction Using Bayesian Networks: An Immunotherapy Case Study in Patients With Metastatic Renal Cell Carcinoma. <i>JCO Clinical Cancer Informatics</i> , 2021, 5, 326-337.  | 1.0 | 4         |
| 18 | Evaluation of the modified immune prognostic index to prognosticate outcomes in metastatic uveal melanoma patients treated with immune checkpoint inhibitors. <i>Cancer Medicine</i> , 2021, 10, 2618-2626.                | 1.3 | 2         |

| #  | ARTICLE  | IF  | CITATIONS |
|----|--|-----|-----------|
| 19 | Real-World Experience of Cabozantinib in Metastatic Renal Cell Carcinoma (mRCC): Results from the Canadian Kidney Cancer information system (CKCis). <i>Kidney Cancer</i> , 2021, 5, 21-29.  | 0.2 | 3         |
| 20 | Assessment of Immune Checkpoint Inhibitors and Genomic Alterations by Body Mass Index in Advanced Renal Cell Carcinoma. <i>JAMA Oncology</i> , 2021, 7, 773.   | 3.4 | 21        |
| 21 | Survival and New Prognosticators in Metastatic Seminoma: Results From the IGCCCG-Update Consortium. <i>Journal of Clinical Oncology</i> , 2021, 39, 1553-1562.   | 0.8 | 83        |
| 22 | Predicting Outcomes in Men With Metastatic Nonseminomatous Germ Cell Tumors (NSGCT): Results From the IGCCCG Update Consortium. <i>Journal of Clinical Oncology</i> , 2021, 39, 1563-1574.   | 0.8 | 108       |
| 23 | Efficacy of immune-checkpoint inhibitors (ICI) in the treatment of older adults with metastatic renal cell carcinoma (mRCC) – an International mRCC Database Consortium (IMDC) analysis. <i>Journal of Geriatric Oncology</i> , 2021, 12, 820-826.                                     | 0.5 | 10        |
| 24 | Association of Concomitant Bone Resorption Inhibitors With Overall Survival Among Patients With Metastatic Castration-Resistant Prostate Cancer and Bone Metastases Receiving Abiraterone Acetate With Prednisone as First-Line Therapy. <i>JAMA Network Open</i> , 2021, 4, e2116536. | 2.8 | 11        |
| 25 | Outcomes of patients with solid tumour malignancies treated with first-line immuno-oncology agents who do not meet eligibility criteria for clinical trials. <i>European Journal of Cancer</i> , 2021, 151, 115-125.   | 1.3 | 22        |
| 26 | Clinical Effectiveness of Second-line Sunitinib Following Immuno-oncology Therapy in Patients with Metastatic Renal Cell Carcinoma: A Real-world Study. <i>Clinical Genitourinary Cancer</i> , 2021, 19, 354-361.  | 0.9 | 5         |
| 27 | Interactive Data Visualization Tool for Patient-Centered Decision Making in Kidney Cancer. <i>JCO Clinical Cancer Informatics</i> , 2021, 5, 912-920.  | 1.0 | 0         |
| 28 | Cabozantinib real-world effectiveness in the first- through fourth-line settings for the treatment of metastatic renal cell carcinoma: Results from the International Metastatic Renal Cell Carcinoma Database Consortium. <i>Cancer Medicine</i> , 2021, 10, 1212-1221.               | 1.3 | 22        |
| 29 | Effectiveness and Safety of First-Line Pembrolizumab in Older Adults with PD-L1 Positive Non-Small Cell Lung Cancer: A Retrospective Cohort Study of the Alberta Immunotherapy Database. <i>Current Oncology</i> , 2021, 28, 4213-4222.  | 0.9 | 10        |
| 30 | The Prognostic Value of Neutrophil-to-Lymphocyte Ratio in Metastatic Testicular Cancer. <i>Current Oncology</i> , 2021, 28, 107-114.   | 0.9 | 10        |
| 31 | Mutational signatures among young-onset testicular cancers. <i>BMC Medical Genomics</i> , 2021, 14, 280.   | 0.7 | 0         |
| 32 | An Update on Predictive Biomarkers in Metastatic Renal Cell Carcinoma. <i>European Urology Focus</i> , 2020, 6, 34-36.   | 1.6 | 25        |
| 33 | The Association Between Small Primary Tumor Size and Prognosis in Metastatic Renal Cell Carcinoma: Insights from Two Independent Cohorts of Patients Who Underwent Cytoreductive Nephrectomy. <i>European Urology Oncology</i> , 2020, 3, 47-56.                                       | 2.6 | 20        |
| 34 | Clinical Outcomes of First-line Sunitinib Followed by Immuno-oncology Checkpoint Inhibitors in Patients With Metastatic Renal Cell Carcinoma. <i>Clinical Genitourinary Cancer</i> , 2020, 18, e350-e359.  | 0.9 | 3         |
| 35 | Prognostic and Predictive Factors in Metastatic Renal Cell Carcinoma. <i>Cancer Journal (Sudbury, Mass)</i> 10.784314 rgBT /Over   | 1.0 | 6         |
| 36 | Efficacy of Savolitinib vs Sunitinib in Patients With <i>MET</i> -Driven Papillary Renal Cell Carcinoma. <i>JAMA Oncology</i> , 2020, 6, 1247.   | 3.4 | 105       |

| #  | ARTICLE  | IF  | CITATIONS |
|----|--|-----|-----------|
| 37 | New insights into the obesity paradox in renal cell carcinoma. <i>Nature Reviews Nephrology</i> , 2020, 16, 253-254.   | 4.1 | 9         |
| 38 | Synchronous Versus Metachronous Metastatic Disease: Impact of Time to Metastasis on Patient Outcome—Results from the International Metastatic Renal Cell Carcinoma Database Consortium. <i>European Urology Oncology</i> , 2020, 3, 530-539.             | 2.6 | 29        |
| 39 | Real-World Assessment of Clinical Outcomes Among First-Line Sunitinib Patients with Clear Cell Metastatic Renal Cell Carcinoma (mRCC) by the International mRCC Database Consortium Risk Group. <i>Oncologist</i> , 2020, 25, 422-430.                   | 1.9 | 12        |
| 40 | Deferred Cytoreductive Nephrectomy in Patients with Newly Diagnosed Metastatic Renal Cell Carcinoma. <i>European Urology</i> , 2020, 78, 615-623.  | 0.9 | 44        |
| 41 | Post-chemotherapy retroperitoneal lymph node dissection for non-seminomatous germ cell tumors: A single-surgeon, Canadian experience. <i>Canadian Urological Association Journal</i> , 2020, 14, E407-E411.  | 0.3 | 2         |
| 42 | Safety and efficacy of restarting immune checkpoint inhibitors after clinically significant immune-related adverse events in metastatic renal cell carcinoma. , 2020, 8, e000144.  |     | 56        |
| 43 | Management of advanced kidney cancer: Kidney Cancer Research Network of Canada (KCRNC) consensus update 2021. <i>Canadian Urological Association Journal</i> , 2020, 15, 84-97.  | 0.3 | 11        |
| 44 | Combining Radiotherapy with Immunocheckpoint Inhibitors or CAR-T in Renal Cell Carcinoma. <i>Current Drug Targets</i> , 2020, 21, 416-423.   | 1.0 | 6         |
| 45 | Nivolumab plus ipilimumab versus sunitinib in first-line treatment for advanced renal cell carcinoma: extended follow-up of efficacy and safety results from a randomised, controlled, phase 3 trial. <i>Lancet Oncology</i> , The, 2019, 20, 1370-1385. | 5.1 | 594       |
| 46 | Management of Advanced Kidney Cancer: Kidney Cancer Research Network of Canada (KCRNC) consensus update 2019. <i>Canadian Urological Association Journal</i> , 2019, 13, 343-54.   | 0.3 | 10        |
| 47 | The Lung Immune Prognostic Index Discriminates Survival Outcomes in Patients with Solid Tumors Treated with Immune Checkpoint Inhibitors. <i>Cancers</i> , 2019, 11, 1713.   | 1.7 | 56        |
| 48 | First-line Immuno-Oncology Combination Therapies in Metastatic Renal-cell Carcinoma: Results from the International Metastatic Renal-cell Carcinoma Database Consortium. <i>European Urology</i> , 2019, 76, 861-867.                                    | 0.9 | 71        |
| 49 | Sequencing and Combination of Systemic Therapy in Metastatic Renal Cell Carcinoma. <i>European Urology Oncology</i> , 2019, 2, 505-514.  | 2.6 | 50        |
| 50 | Cabozantinib in advanced non-clear-cell renal cell carcinoma: a multicentre, retrospective, cohort study. <i>Lancet Oncology</i> , The, 2019, 20, 581-590.   | 5.1 | 124       |
| 51 | Cytoreductive Nephrectomy in Metastatic Papillary Renal Cell Carcinoma: Results from the International Metastatic Renal Cell Carcinoma Database Consortium. <i>European Urology Oncology</i> , 2019, 2, 643-648.   | 2.6 | 31        |
| 52 | The evolving role of cytoreductive nephrectomy in metastatic renal cell carcinoma. <i>Current Opinion in Urology</i> , 2019, 29, 507-512.  | 0.9 | 10        |
| 53 | First-line Systemic Therapy for Metastatic Renal Cell Carcinoma: A Systematic Review and Network Meta-analysis. <i>European Urology</i> , 2018, 74, 309-321.   | 0.9 | 51        |
| 54 | Real-world evidence in metastatic renal cell carcinoma. <i>Tumori</i> , 2018, 104, 76-82.  | 0.6 | 11        |

| #  | ARTICLE  | IF  | CITATIONS |
|----|--|-----|-----------|
| 55 | Prognostication in Kidney Cancer: Recent Advances and Future Directions. Journal of Clinical Oncology, 2018, 36, 3567-3573.  | 0.8 | 49        |
| 56 | Personalized Management of Advanced Kidney Cancer. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2018, 38, 330-341.   | 1.8 | 25        |
| 57 | Checkpoint inhibitors in patients with metastatic renal cell carcinoma: Results from the International Metastatic Renal Cell Carcinoma Database Consortium. Cancer, 2018, 124, 3677-3683.  | 2.0 | 53        |
| 58 | Safety and efficacy of nivolumab in combination with sunitinib or pazopanib in advanced or metastatic renal cell carcinoma: the CheckMate 016 study. , 2018, 6, 109.   |     | 151       |
| 59 | Fourth-Line Therapy in Metastatic Renal Cell Carcinoma (mRCC): Results from the International mRCC Database Consortium (IMDC)1. Kidney Cancer, 2018, 2, 31-36.   | 0.2 | 10        |
| 60 | Third-line Targeted Therapy in Metastatic Renal Cell Carcinoma: Results from the International Metastatic Renal Cell Carcinoma Database Consortium. European Urology, 2017, 71, 204-209.   | 0.9 | 65        |
| 61 | Predictive and Prognostic Markers in Metastatic Renal Cell Carcinoma. , 2017, , 237-251.   |     | 0         |
| 62 | Molecular Subtypes Improve Prognostic Value of International Metastatic Renal Cell Carcinoma Database Consortium Prognostic Model. Oncologist, 2017, 22, 286-292.  | 1.9 | 54        |
| 63 | Characterizing the outcomes of metastatic papillary renal cell carcinoma. Cancer Medicine, 2017, 6, 902-909.   | 1.3 | 37        |
| 64 | On-treatment biomarkers in metastatic renal cell carcinoma: towards individualization of prognosis?. Expert Review of Anticancer Therapy, 2017, 17, 97-99.   | 1.1 | 3         |
| 65 | Adjuvant therapy in renal cell carcinoma. Cancer Treatment Reviews, 2017, 60, 152-157.   | 3.4 | 35        |
| 66 | In Reply. Oncologist, 2017, 22, 1561-1561.   | 1.9 | 0         |
| 67 | Efficacy of Second-line Targeted Therapy for Renal Cell Carcinoma According to Change from Baseline in International Metastatic Renal Cell Carcinoma Database Consortium Prognostic Category. European Urology, 2017, 71, 970-978. | 0.9 | 12        |
| 68 | The kidney cancer research priority-setting partnership: Identifying the top 10 research priorities as defined by patients, caregivers, and expert clinicians. Canadian Urological Association Journal, 2017, 11, 379-87.          | 0.3 | 29        |
| 69 | First-line sunitinib or pazopanib in metastatic renal cell carcinoma: The Canadian experience. Canadian Urological Association Journal, 2017, 11, 112.   | 0.3 | 32        |
| 70 | Safety and Efficacy of Nivolumab in Combination With Ipilimumab in Metastatic Renal Cell Carcinoma: The CheckMate 016 Study. Journal of Clinical Oncology, 2017, 35, 3851-3858.  | 0.8 | 384       |
| 71 | Biomarker-Based Phase II Trial of Savolitinib in Patients With Advanced Papillary Renal Cell Cancer. Journal of Clinical Oncology, 2017, 35, 2993-3001.  | 0.8 | 145       |
| 72 | Contemporary treatment of metastatic renal cell carcinoma. Oncology Reviews, 2016, 10, 295.  | 0.8 | 32        |

| #  | ARTICLE   | IF   | CITATIONS |
|----|---|------|-----------|
| 73 | Risk factors and model for predicting toxicity-related treatment discontinuation in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor-targeted therapy: Results from the International Metastatic Renal Cell Carcinoma Database Consortium. <i>Cancer</i> , 2016, 122, 411-419. | 2.0  | 27        |
| 74 | Cabozantinib in the treatment of advanced renal cell carcinoma: clinical trial evidence and experience. <i>Therapeutic Advances in Urology</i> , 2016, 8, 338-347.  | 0.9  | 20        |
| 75 | Body Mass Index and Metastatic Renal Cell Carcinoma: Clinical and Biological Correlations. <i>Journal of Clinical Oncology</i> , 2016, 34, 3655-3663.   | 0.8  | 174       |
| 76 | Improvement in survival end points of patients with metastatic renal cell carcinoma through sequential targeted therapy. <i>Cancer Treatment Reviews</i> , 2016, 50, 109-117.   | 3.4  | 64        |
| 77 | The prospect of precision therapy for renal cell carcinoma. <i>Cancer Treatment Reviews</i> , 2016, 49, 37-44.  | 3.4  | 46        |
| 78 | First-line sunitinib versus pazopanib in metastatic renal cell carcinoma: Results from the International Metastatic Renal Cell Carcinoma Database Consortium. <i>European Journal of Cancer</i> , 2016, 65, 102-108.  | 1.3  | 60        |
| 79 | Adult patient perspectives on clinical trial result reporting: A survey of cancer patients. <i>Clinical Trials</i> , 2016, 13, 574-581.   | 0.7  | 17        |
| 80 | Cabozantinib versus everolimus in advanced renal cell carcinoma (METEOR): final results from a randomised, open-label, phase 3 trial. <i>Lancet Oncology</i> , The, 2016, 17, 917-927.  | 5.1  | 789       |
| 81 | Mutations in TSC1, TSC2, and MTOR Are Associated with Response to Rapalogs in Patients with Metastatic Renal Cell Carcinoma. <i>Clinical Cancer Research</i> , 2016, 22, 2445-2452.   | 3.2  | 193       |
| 82 | Change in Neutrophil-to-lymphocyte Ratio in Response to Targeted Therapy for Metastatic Renal Cell Carcinoma as a Prognosticator and Biomarker of Efficacy. <i>European Urology</i> , 2016, 70, 358-364.  | 0.9  | 133       |
| 83 | Review of the Interaction Between Body Composition and Clinical Outcomes in Metastatic Renal Cell Cancer Treated with Targeted Therapies. <i>Journal of Kidney Cancer and VHL</i> , 2016, 3, 12-22.   | 0.2  | 6         |
| 84 | Management of advanced kidney cancer: Canadian Kidney Cancer Forum consensus update. <i>Canadian Urological Association Journal</i> , 2015, 9, 164.   | 0.3  | 18        |
| 85 | New molecular targets in non clear renal cell carcinoma: An overview of ongoing clinical trials. <i>Cancer Treatment Reviews</i> , 2015, 41, 614-622.   | 3.4  | 19        |
| 86 | The promise of futility trials in neurological diseases. <i>Nature Reviews Neurology</i> , 2015, 11, 300-305.   | 4.9  | 16        |
| 87 | Metastatic renal cell carcinoma: Contending with a sea change in therapy. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2015, 33, 507-508.   | 0.8  | 8         |
| 88 | The International Metastatic Renal Cell Carcinoma Database Consortium model as a prognostic tool in patients with metastatic renal cell carcinoma previously treated with first-line targeted therapy: a population-based study. <i>Lancet Oncology</i> , The, 2015, 16, 293-300.   | 5.1  | 299       |
| 89 | The use of prognostic factors in metastatic renal cell carcinoma. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2015, 33, 509-516.   | 0.8  | 32        |
| 90 | Cabozantinib versus Everolimus in Advanced Renal-Cell Carcinoma. <i>New England Journal of Medicine</i> , 2015, 373, 1814-1823.   | 13.9 | 1,004     |

| #   | ARTICLE   | IF  | CITATIONS |
|-----|---|-----|-----------|
| 91  | Characterizing the Impact of Lymph Node Metastases on the Survival Outcome for Metastatic Renal Cell Carcinoma Patients Treated with Targeted Therapies. <i>European Urology</i> , 2015, 68, 506-515.   | 0.9 | 41        |
| 92  | Efficacy of targeted therapies after PD-1/PD-L1 blockade in metastatic renal cell carcinoma. <i>European Journal of Cancer</i> , 2015, 51, 2580-2586.   | 1.3 | 79        |
| 93  | Characteristics of Long-Term and Short-Term Survivors of Metastatic Renal Cell Carcinoma Treated With Targeted Therapies: Results From the International mRCC Database Consortium. <i>Clinical Genitourinary Cancer</i> , 2015, 13, 150-155.                            | 0.9 | 10        |
| 94  | Progression-free survival as primary endpoint in randomized clinical trials of targeted agents for advanced renal cell carcinoma. Correlation with overall survival, benchmarking and power analysis. <i>Critical Reviews in Oncology/Hematology</i> , 2015, 93, 50-59. | 2.0 | 14        |
| 95  | Outcomes with Abiraterone Acetate in Metastatic Castration-resistant Prostate Cancer Patients Who Have Poor Performance Status. <i>European Urology</i> , 2015, 67, 441-447.  | 0.9 | 40        |
| 96  | Clinical Prognostic Factors in Metastatic Renal Cell Carcinoma. , 2015, , 555-567.  |     | 0         |
| 97  | Independent Predictors of Clinical Outcomes and Prediction Models for Renal Tumor Pathology. , 2015, , 355-371.   |     | 2         |
| 98  | Current management and future perspectives of metastatic renal cell carcinoma. <i>International Journal of Urology</i> , 2014, 21, 847-855.   | 0.5 | 27        |
| 99  | Management of metastatic kidney cancer in the era of personalized medicine. <i>Critical Reviews in Clinical Laboratory Sciences</i> , 2014, 51, 85-97.  | 2.7 | 6         |
| 100 | Efficacy of Targeted Therapy for Metastatic Renal Cell Carcinoma in the Elderly Patient Population. <i>Clinical Genitourinary Cancer</i> , 2014, 12, 354-358.   | 0.9 | 26        |
| 101 | Prognostic Significance of Bone Metastases and Bisphosphonate Therapy in Patients with Renal Cell Carcinoma. <i>European Urology</i> , 2014, 66, 502-509.   | 0.9 | 68        |
| 102 | Impact of Bone and Liver Metastases on Patients with Renal Cell Carcinoma Treated with Targeted Therapy. <i>European Urology</i> , 2014, 65, 577-584.   | 0.9 | 207       |
| 103 | Everolimus plus exemestane as first-line therapy in HR+, HER2 <sup>+</sup> advanced breast cancer in BOLERO-2. <i>Breast Cancer Research and Treatment</i> , 2014, 143, 459-467.  | 1.1 | 74        |
| 104 | A retrospective, Canadian multi-center study examining the impact of prior response to abiraterone acetate on efficacy of docetaxel in metastatic castration-resistant prostate cancer. <i>Prostate</i> , 2014, 74, 1544-1550.  | 1.2 | 45        |
| 105 | Cytoreductive Nephrectomy in Patients with Synchronous Metastases from Renal Cell Carcinoma: Results from the International Metastatic Renal Cell Carcinoma Database Consortium. <i>European Urology</i> , 2014, 66, 704-710.   | 0.9 | 382       |
| 106 | The Impact of Low Serum Sodium on Treatment Outcome of Targeted Therapy in Metastatic Renal Cell Carcinoma: Results from the International Metastatic Renal Cell Cancer Database Consortium. <i>European Urology</i> , 2014, 65, 723-730.                               | 0.9 | 69        |
| 107 | A Population-Based Overview of Sequences of Targeted Therapy in Metastatic Renal Cell Carcinoma. <i>Clinical Genitourinary Cancer</i> , 2014, 12, e127-e131.  | 0.9 | 25        |
| 108 | Considerations for the Design of Future Clinical Trials in Metastatic Renal Cell Carcinoma. <i>Clinical Genitourinary Cancer</i> , 2014, 12, 1-12.  | 0.9 | 7         |

| #   | ARTICLE   | IF  | CITATIONS |
|-----|---|-----|-----------|
| 109 | Survival Outcome and Treatment Response of Patients with Late Relapse from Renal Cell Carcinoma in the Era of Targeted Therapy. <i>European Urology</i> , 2014, 65, 1086-1092.  | 0.9 | 71        |
| 110 | Programmed Death 1 Pathway inhibition in Metastatic Renal Cell Cancer and Prostate Cancer. <i>Current Oncology Reports</i> , 2013, 15, 98-104.  | 1.8 | 41        |
| 111 | The association of clinical outcome to first-line VEGF-targeted therapy with clinical outcome to second-line VEGF-targeted therapy in metastatic renal cell carcinoma patients. <i>Targeted Oncology</i> , 2013, 8, 203-209.  | 1.7 | 47        |
| 112 | Metastatic non-clear cell renal cell carcinoma treated with targeted therapy agents: Characterization of survival outcome and application of the International mRCC Database Consortium criteria. <i>Cancer</i> , 2013, 119, 2999-3006.   | 2.0 | 189       |
| 113 | Prognostic Factors of Survival for Patients With Metastatic Renal Cell Carcinoma With Brain Metastases Treated With Targeted Therapy: Results From the International Metastatic Renal Cell Carcinoma Database Consortium. <i>Clinical Genitourinary Cancer</i> , 2013, 11, 311-315.   | 0.9 | 64        |
| 114 | External validation and comparison with other models of the International Metastatic Renal-Cell Carcinoma Database Consortium prognostic model: a population-based study. <i>Lancet Oncology</i> , The, 2013, 14, 141-148.  | 5.1 | 808       |
| 115 | Prognostic Factors in Advanced Renal Cell Carcinoma. , 2013, , 249-255.   |     | 0         |
| 116 | Canadian guideline on genetic screening for hereditary renal cell cancers. <i>Canadian Urological Association Journal</i> , 2013, 7, 319.   | 0.3 | 30        |
| 117 | Health-related quality of life and disease symptoms in postmenopausal women with HR <sup>+</sup> , HER2 <sup>-</sup> advanced breast cancer treated with everolimus plus exemestane versus exemestane monotherapy. <i>Current Medical Research and Opinion</i> , 2013, 29, 1463-1473. | 0.9 | 24        |
| 118 | Primary anti-vascular endothelial growth factor (VEGF)-refractory metastatic renal cell carcinoma: clinical characteristics, risk factors, and subsequent therapy. <i>Annals of Oncology</i> , 2012, 23, 1549-1555.   | 0.6 | 121       |
| 119 | Conditional survival of patients with metastatic renal-cell carcinoma treated with VEGF-targeted therapy: a population-based study. <i>Lancet Oncology</i> , The, 2012, 13, 927-935.  | 5.1 | 112       |
| 120 | The impact of kidney function on the outcome of metastatic renal cell carcinoma patients treated with vascular endothelial growth factor-targeted therapy. <i>Cancer</i> , 2012, 118, 365-370.  | 2.0 | 21        |
| 121 | The Evolving Landscape of Metastatic Renal Cell Carcinoma. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2012, , 299-302.  | 1.8 | 10        |
| 122 | The Impact of Cytoreductive Nephrectomy on Survival of Patients With Metastatic Renal Cell Carcinoma Receiving Vascular Endothelial Growth Factor Targeted Therapy. <i>Journal of Urology</i> , 2011, 185, 60-66.   | 0.2 | 322       |
| 123 | Clinical and Molecular Prognostic Factors in Renal Cell Carcinoma: What We Know So Far. <i>Hematology/Oncology Clinics of North America</i> , 2011, 25, 871-891.  | 0.9 | 27        |
| 124 | Combination therapy in metastatic renal cell carcinoma. <i>Lancet Oncology</i> , The, 2011, 12, 613-614.  | 5.1 | 1         |
| 125 | Comparison of Four Early Posttherapy Imaging Changes (EPTIC; RECIST 1.0, Tumor Shrinkage, Computed) Tj ETQq1 1 0.784314 rgBT<br>Factor-targeted Therapy in Patients With Advanced Renal Cell Carcinoma. <i>European Urology</i> , 2011, 59, 856-862.                                  | 0.9 | 99        |
| 126 | Progression-free survival as a predictor of overall survival in metastatic renal cell carcinoma treated with contemporary targeted therapy. <i>Cancer</i> , 2011, 117, 2637-2642.   | 2.0 | 74        |



| #   | ARTICLE   | IF  | CITATIONS |
|-----|---|-----|-----------|
| 127 | Prognostic Model for Survival in Patients with Metastatic Renal Cell Carcinoma: Results from the International Kidney Cancer Working Group. <i>Clinical Cancer Research</i> , 2011, 17, 5443-5450.  | 3.2 | 164       |
| 128 | Prognostic and predictive biomarkers in renal cell carcinoma. <i>Targeted Oncology</i> , 2010, 5, 85-94.  | 1.7 | 27        |
| 129 | Vascular endothelial growth factor-targeted therapy for the treatment of adult metastatic Xp11.2 translocation renal cell carcinoma. <i>Cancer</i> , 2010, 116, 5219-5225.  | 2.0 | 121       |
| 130 | Sunitinib rechallenge in metastatic renal cell carcinoma patients. <i>Cancer</i> , 2010, 116, 5400-5406.  | 2.0 | 123       |
| 131 | Prognostic Factors for Overall Survival in Patients With Metastatic Renal Cell Carcinoma Treated With Vascular Endothelial Growth Factor-targeted Agents: Results From a Large, Multicenter Study. <i>Journal of Clinical Oncology</i> , 2009, 27, 5794-5799. | 0.8 | 1,751     |
| 132 | A population-based study evaluating the impact of sunitinib on overall survival in the treatment of patients with metastatic renal cell cancer. <i>Cancer</i> , 2009, 115, 776-783.   | 2.0 | 63        |
| 133 | Non-Clear Cell Renal Cancer: Features and Medical Management. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2009, 7, 659-665.  | 2.3 | 32        |
| 134 | Anti-Angiogenic Targets in the Treatment of Advanced Renal Cell Carcinoma. <i>Current Cancer Drug Targets</i> , 2008, 8, 676-682.   | 0.8 | 38        |
| 135 | Prolonged Complete Responses and Near-Complete Responses to Sunitinib in Metastatic Renal Cell Carcinoma. <i>Clinical Genitourinary Cancer</i> , 2007, 5, 446-451.  | 0.9 | 30        |